885685-70-1

Basic information

• Product Name: Methyl 2-Mercaptothiazole-5-carboxylate
• Synonyms: Methyl 2-Mercaptothiazole-5-carboxylate;2,3-Dihydro-2-thioxo-5-thiazolecarboxylic acid methyl ester;2-Mercaptothiazole-5-carboxylic acid methyl ester
• CAS NO: 885685-70-1
• Molecular Formula: C5H5NO2S2
• Molecular Weight: 175.2287
• Mol File: 885685-70-1.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 273℃
• Flash Point: 119℃
• Appearance: /
• Density: 1.50
• PKA: 7.27±0.40(Predicted)
• CAS DataBase Reference: Methyl 2-Mercaptothiazole-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-Mercaptothiazole-5-carboxylate(885685-70-1)
• EPA Substance Registry System: Methyl 2-Mercaptothiazole-5-carboxylate(885685-70-1)

Safety Data

• Hazardous Substances Data: 885685-70-1(Hazardous Substances Data)

Usage

General Description

Methyl 2-Mercaptothiazole-5-carboxylate is a chemical compound with the molecular formula C6H5NO2S2. It is a thiazole derivative with a sulfur-containing functional group, specifically a mercaptothiazole. Methyl 2-Mercaptothiazole-5-carboxylate is commonly used as a building block in the synthesis of pharmaceuticals, agrochemicals, and materials. It has also been reported to possess antimicrobial properties, making it potentially useful in the development of new antibiotics and disinfectants. Additionally, it is known to exhibit strong odor and is used as a flavoring agent in the food industry. Methyl 2-Mercaptothiazole-5-carboxylate is typically handled with care due to its potential hazards and is subject to regulations in its use and handling.

Upstream product

• 54045-74-8 methyl 2-bromo-1,3-thiazole-5-carboxylate 
• 17356-08-0 thiourea 

Relevant articles and documents

LOX ENZYME INHIBITING METHODS AND COMPOSITIONS

This invention relates to compounds, pharmaceutical compositions and their use for treating fibrotic disorders, proliferative disorders, cardiovascular diseases, acute and chronic inflammatory disorders, primary and metastatic cancer, pulmonary conditions, ocular diseases, or neurological and neuropsychiatric conditions. One particular aspect of the inventions relates to inhibitors of the family of lysyl oxidase enzymes and their use as therapeutics for fibrotic disorders.

NLRP3 INHIBITORS

The present application relates to compounds with NLRP3inhibitory activity and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present application further relates to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3inhibition.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.